Comparative Pharmacology
Head-to-head clinical analysis: BETAPEN VK versus CYCLAPEN W.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPEN VK versus CYCLAPEN W.
BETAPEN-VK vs CYCLAPEN-W
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan synthesis, leading to cell lysis.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections; up to 500 mg orally every 4 hours for severe infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours with creatinine clearance <10 mL/min.
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Renal excretion accounts for 20-40% of the dose as unchanged drug via tubular secretion and glomerular filtration; biliary/fecal excretion is minimal (<10%).
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic